« Back
Home /
Pioglitazone

Pioglitazone

€130.00

Excl. VAT

Item no.	HY-13956-50mg
Manufacturer	MedChem Express
CASRN	111025-46-8
Amount	50 mg
Category	Oncology Neuroscience Neural Lineage Markers Metabolism Diabetes Cholesterol & Lipid Metabolism Regulation of Appetite Cardiovascular Research Atherosclerosis Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Colorectal Cancer Testicular & Prostate Cancer Neurodegeneration Markers;Research Area Neuroinflammation
Type	Inhibitors
Specific against	other
Purity	99.66
Formula	C19H20N2O3S
Citations	Acta Pharmacol Sin. 2021 Jan;42(1):160-170. Am J Physiol Heart Circ Physiol. 2021 Apr 9. Am J Physiol Renal Physiol. 2019 Jul 1;317(1):F137-F151. Biochem Eng J. 2021, 108104. BMC Complement Med Ther. 2022 Jul 1;22(1):176. Br J Pharmacol. 2021 Jun;178(11):2305-2323. Cancer Res. 2022 Apr 15;82(8):1503-1517. Cell Metab. 2021 Mar 2;33(3):581-597.e9. Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9. Food Chem Toxicol. 2021 Apr 6;112183. Gut Microbes. 2022, 14(1): 2139978. Heliyon. 2023 Apr 1. Immunology. 2023 Jan 28. Immunopharmacol Immunotoxicol. 2021 Aug 27;1-9. J Steroid Biochem Mol Biol. 2023 Feb 1;229:106265. Med Sci Monit. 2019 Nov 13;25:8544-8553. Nutr Metab (Lond). 2019 Mar 5;16:17. Oxid Med Cell Longev. 2022. Research Square Preprint. 2021 Mar. SSRN. 2023 May 30. Inflammation. 2020 Apr;43(2):568-578. Int J Oncol. 2018 Aug;53(2):551-566. J Diabetes Res. 2019 Feb 3;2019:5245063. Mol Med Rep. 2019 Jan;19(1):400-406. [1]Kuwabara K, et al. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose leve [2]Puddu A, et al. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regul Pept. 2012 Aug 20;177(1-3):79-84. [3]Kubota N, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006 Mar 31;281(13):8748-55. [4]Elrashidy RA, et al. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):324-33.
Smiles	O=C(N1)SC(CC2=CC=C(OCCC3=NC=C(CC)C=C3)C=C2)C1=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	U 72107
Available
Product Description	Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research[2][3][4].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
Molecular Weight	356.44
Clinical Information	Launched
Solubility	DMSO : 40 mg/mL (ultrasonic; warming; heat to 60°C)
Isoform	PPARα; PPARβ/δ; PPARγ
Pathway	Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13956-50mg-safety-datasheet.pdf